{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:05:06Z","timestamp":1770822306221,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1053\/j.seminhematol.2004.02.007","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T13:00:54Z","timestamp":1086786054000},"page":"18-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"S3","title":["Treatment paradigms in the management of myeloproliferative disorders"],"prefix":"10.1053","volume":"41","author":[{"given":"Steven M","family":"Fruchtman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2004.02.007_BIB1","series-title":"Polycythemia, Erythrocytosis, and Erythraemia (Vaquez-Osler Disease)","author":"Weber","year":"1922"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB2","first-page":"266","article-title":"Comments on the therapy of polycythemia vera","volume":"3","author":"Dameshek","year":"1966","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0002-9343(67)90075-7","article-title":"Polycythemia vera complicated by acute leukemia and a rapidly enlarging mass in the left upper abdominal quadrant","volume":"42","author":"Moore","year":"1967","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB5","first-page":"147","article-title":"Epidemiology of polycythemia vera in Cte d\u2019Or (Burgundy)","volume":"36","author":"Carli","year":"1994","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.0954-6820.1962.tb07186.x","article-title":"Complications and causes of death in polycythemia vera","volume":"172","author":"Chievitz","year":"1962","journal-title":"Acta Med Scand"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJM198102193040801","article-title":"Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy","volume":"304","author":"Berk","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB8","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2141.2002.03763.x","article-title":"Exploring polycythaemia vera with fluorescence in situ hybridization","volume":"119","author":"Najfeld","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB11","first-page":"214","article-title":"Karyotypic patterns in chronic myeloproliferative disorders","volume":"5","author":"Mertens","year":"1991","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB13","first-page":"17","article-title":"From efficacy to safety","volume":"34","author":"Fruchtman","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB14","first-page":"801a","article-title":"Prognostic implications of gain of 9p, the most frequent cytogenetic alteration in polycythemia vera (PV)","volume":"100","author":"Stein","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB15","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/blood-2002-03-0949","article-title":"Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera","volume":"100","author":"Klippel","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0301-472X(02)01032-9","article-title":"Fluorescence in situ hybridization analysis of the PRV-1 gene in polycythemia vera","volume":"31","author":"Najfeld","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2004.02.007_BIB18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10428199609074368","article-title":"Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera","volume":"22","author":"Najean","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB19","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJM198805193182002","article-title":"Anagrelide","volume":"318","author":"Silverstein","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2004.02.007_BIB20","first-page":"70a","article-title":"Anagrelide","volume":"100","author":"Fruchtman","year":"2002","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196304000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196304000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:12:28Z","timestamp":1758521548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196304000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":20,"alternative-id":["S0037196304000356"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2004.02.007","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment paradigms in the management of myeloproliferative disorders","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2004.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}